My ePortfolio Register   

Increased long-term risk of breast cancer with high intra-tumour ER hetrogeneity

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.17
Views: 597

Dr Linda Lindström - University of California at San Francisco, San Francisco, USA

Dr Lindström speaks with ecancer at IMPAKT 2017 about STO-3, a historic trial of breast cancer patients treated with or without tamoxifen.

She describes the survival impact of intra-tumour heterogeneity for oestrogen receptor (ER), especially among luminal A tumour subtypes.

Dr Lindström outlines further long-term follow up studies in the STO-2 trial, and considers the clinical value of risk stratification.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence